# Abatacept Versus Adalimumab Head-to-Head

> **NCT00929864** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 869 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT00929864
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-10
- **Final completion:** 2012-11
- **Target enrollment:** 869 (ACTUAL)
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929864, "Abatacept Versus Adalimumab Head-to-Head". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00929864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*